1. Home
  2. CNOB vs ARDX Comparison

CNOB vs ARDX Comparison

Compare CNOB & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

HOLD

Current Price

$30.02

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$7.14

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNOB
ARDX
Founded
1982
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CNOB
ARDX
Price
$30.02
$7.14
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$31.25
$15.14
AVG Volume (30 Days)
326.7K
3.7M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,607,000.00
Revenue This Year
$42.85
$37.75
Revenue Next Year
$7.27
$34.24
P/E Ratio
$17.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.82
$3.50
52 Week High
$30.15
$8.40

Technical Indicators

Market Signals
Indicator
CNOB
ARDX
Relative Strength Index (RSI) 66.18 68.32
Support Level $25.08 $6.83
Resistance Level N/A $8.23
Average True Range (ATR) 0.90 0.36
MACD 0.07 0.13
Stochastic Oscillator 79.71 82.61

Price Performance

Historical Comparison
CNOB
ARDX

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: